EQ-5D | SF-6D | Difference | |
---|---|---|---|
(EQ-5D vs. SF-6D) | |||
Patient subgroups | |||
Patients who completed the trial and had no adverse events | 0.695 | 0.694 | 0.001 |
Patients with at least one AE | 0.583 | 0.640 | −0.057 |
Patients with an AE that lead to withdrawal | 0.503 | 0.594 | −0.091 |
Patients who discontinued therapy due to lack of efficacy | 0.405 | 0.582 | −0.176 |
WOMAC severity level at baseline | |||
None to mild | 0.740 | 0.717 | 0.023 |
Mild to moderate | 0.550 | 0.616 | −0.066 |
Moderate to severe | 0.311 | 0.536 | −0.225 |
Severe to extreme | 0.180 | 0.461 | −0.281 |